A5035048733- Influenza Virus Research Studies
- Respiratory viral infections research
- Immune Response and Inflammation
- SARS-CoV-2 and COVID-19 Research
- Diabetes and associated disorders
- Animal Disease Management and Epidemiology
- Pneumonia and Respiratory Infections
- Viral Infections and Immunology Research
- Receptor Mechanisms and Signaling
- Vaccine Coverage and Hesitancy
GlaxoSmithKline (Belgium)
2018-2024
Vaccine responsiveness is often reduced in older adults. Yet, our lack of understanding low vaccine hampers the development effective vaccination strategies to reduce impact infectious diseases ageing population. Young-adult (25–49 y), middle-aged (50-64 y) and older-adult ( ≥ 65 participants VITAL clinical trials (n = 315, age-range: 28-98 were vaccinated with an annual (2019–2020) quadrivalent influenza (QIV) booster vaccine, followed by a primary 13-valent pneumococcal-conjugate (PCV13)...
The haemagglutination inhibition assay (HAI) and the virus microneutralisation (MN) are long-established methods for quantifying antibodies against influenza viruses. Despite their widespread use, both assays require standardisation to improve inter-laboratory agreement in testing. FLUCOP consortium aims develop a toolbox of standardised serology seasonal influenza. Building upon previous collaborative studies harmonise HAI, this study carried out head-to-head comparison harmonised HAI MN...
Current vaccination strategies against influenza focus on generating an antibody response the viral haemagglutination surface protein, however there is increasing interest in neuraminidase (NA) as a target for vaccine development. A critical tool development of vaccines that NA or include component available validated serology assays quantifying anti-NA antibodies. Additionally have role defining correlates protection and licensure. Standardisation these important consistent accurate...
The hemagglutination inhibition (HAI) assay is the most commonly used serology to detect antibodies from influenza vaccination or virus infection. This has been for decades but requires improved standardization of procedures provide meaningful data.
Abstract Vaccine responsiveness is often reduced in older adults. Yet, our lack of understanding low vaccine hampers the development effective vaccination strategies to reduce impact infectious diseases ageing population. Young-adult, middle-aged and older-adult participants VITAL clinical trials (n=315, age range: 28-98y), were consecutively vaccinated with a booster quadrivalent influenza (QIV) vaccine, primary 13-valent pneumococcal-conjugate (PCV13) series SARS-CoV2 mRNA-1273 vaccines...
Abstract Background A single-dose investigational respiratory syncytial virus (RSV) vaccine, RSV prefusion protein F3 (RSVPreF3), was co-administered with a quadrivalent influenza vaccine (FLU-D-QIV) in phase 3, randomized, controlled, multicenter study healthy, nonpregnant women aged 18–49 years. Methods The observer-blind to evaluate the lot-to-lot consistency of RSVPreF3, and single-blind immune response, safety, reactogenicity RSVPreF3 FLU-D-QIV. Results total 1415 participants were...
Abstract Background Non‐neutralizing antibodies inducing complement‐dependent lysis (CDL) and antibody‐dependent cell‐mediated cytotoxicity (ADCC) activity may contribute to protection against influenza infection. We investigated CDL ADCC responses in healthy adults randomized receive either non‐adjuvanted or AS03‐adjuvanted monovalent A(H1N1)pdm09 vaccine (containing 15 µg/3.75 μg of hemagglutinin, respectively) on a 2‐dose schedule 21 days apart. Methods conducted an exploratory analysis...
ABSTRACT Background Influenza A/Hong Kong/125/2017 (H7N9) virus poses a pandemic risk owing to its evolving nature. This study evaluated the immunogenicity and safety of an AS03‐adjuvanted H7N9 vaccine in adults (18–64 years [younger] ≥65 [older]). Methods Participants (younger, n = 418; older, 420) were randomized receive one six adjuvanted vaccines (hemagglutinin [1.9 μg, 3.75 7.5 μg] with AS03 A or B ) placebo. The co‐primary objectives determine whether elicit immune response against...
Background: It has not yet been demonstrated whether 2 doses of inactivated quadrivalent influenza vaccine (IIV4) prime a booster response in infants. We evaluated the anamnestic immune to an IIV4 children 17−48 months age. Methods: Children were randomized or control primary phase III study (NCT01439360). One year later, open-label revaccination extension (NCT01702454), subset who received (primed group) 1 dose and (unprimed) 28 days apart. The objective was evaluate hemagglutination...